Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith

Patent metadata

Field	Value
Publication number	US-2025059154-A1
Application number	US-202418770647-A
Country	US
Kind code	A1
Filing date	Jul 11, 2024
Priority date	Jun 20, 2018
Publication date	Feb 20, 2025
Grant date	—

Abstract

Provided herein are compounds, compositions and methods for treating and preventing diseases and disorders, comprising administering to patients therapeutically effective amounts of cysteine-dependent inverse agonists of the nuclear receptor RORγ/RORγt. In some such embodiments, the inverse agonists bind to cysteine 476 of a nuclear receptor RORγ in the patient. Also provided are methods, as well as compounds and compositions, for modulating the activity of RORγ and RORγt by binding to the allosteric binding site through a covalent bond. In some aspects, the present disclosure relates to using compounds containing Michael acceptor groups which bind to a cysteine residue in the allosteric binding site such as cysteine 476 in RORγ.

First claim

1 . A method of treating a disease or disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a cysteine-dependent inverse agonist of the nuclear receptor RORγ/RORγt.

2 .- 165 . (canceled)

166 . A compound of the formula:

or a pharmaceutically acceptable salt thereof.

167 . A pharmaceutical composition comprising:
(A) a compound according to claim 166 ; and (B) an excipient.

168 . The pharmaceutical composition of claim 167 , wherein the pharmaceutical composition is formulated for administration: orally, intraadiposally, intraarterially, intraarticularly, intracranially, intradermally, intralesionally, intramuscularly, intranasally, intraocularly, intrapericardially, intraperitoneally, intrapleurally, intraprostatically, intrarectally, intrathecally, intratracheally, intratumorally, intraumbilically, intravaginally, intravenously, intravesicularlly, intravitreally, liposomally, locally, mucosally, parenterally, rectally, subconjunctival, subcutaneously, sublingually, topically, transbuccally, transdermally, vaginally, in cremes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, or via localized perfusion.

169 . The pharmaceutical composition of claim 168 , wherein the pharmaceutical composition is formulated for oral administration.

170 . The pharmaceutical composition of claim 168 , wherein the pharmaceutical composition is formulated for administration via injection.

171 . The pharmaceutical composition of claim 170 , wherein the pharmaceutical composition is formulated for intraarterial administration, intramuscular administration, intraperitoneal administration, or intravenous administration.

172 . The pharmaceutical composition of claim 168 , wherein the pharmaceutical composition is formulated for administration topically.

173 . The pharmaceutical composition of claim 172 , wherein the pharmaceutical composition is formulated for topical administration to the skin or to the eye.

174 . The pharmaceutical composition of claim 167 , wherein the pharmaceutical composition is formulated as a unit dose.

175 . The compound of claim 166 further defined as:

or a pharmaceutically acceptable salt thereof.

176 . The compound of claim 166 further defined as:

or a pharmaceutically acceptable salt thereof.

177 . The compound of claim 166 further defined as:

or a pharmaceutically acceptable salt thereof.

178 . The compound of claim 166 further defined as:

or a pharmaceutically acceptable salt thereof.

179 . The compound of claim 166 further defined as:

or a pharmaceutically acceptable salt thereof.

180 . The pharmaceutical composition of claim 167 , wherein the compound is further defined as:

or a pharmaceutically acceptable salt thereof.

181 . The pharmaceutical composition of claim 167 , wherein the compound is further defined as:

or a pharmaceutically acceptable salt thereof.

182 . The pharmaceutical composition of claim 167 , wherein the compound is further defined as:

or a pharmaceutically acceptable salt thereof.

183 . The pharmaceutical composition of claim 167 , wherein the compound is further defined as:

or a pharmaceutically acceptable salt thereof.

184 . The pharmaceutical composition of claim 167 , wherein the compound is further defined as:

or a pharmaceutically acceptable salt thereof.

Assignees

• Reata Pharmaceuticals Inc

Inventors

• Visnick Melean
• Jiang Xin

Classifications

• C07D403/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P17/06

  Antipsoriatics · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61K31/4192

  1,2,3-Triazoles · CPC title